Valeo Pharma Inc. News

Valeo Pharma Reports Its Second Quarter 2022 Results and Highlights

Q2-22 revenues of $4.8 million, up 80% over Q2-21 Q2-22 gross margins of $1.7 million, up 134% over Q2-21 Canadian provincial public […]


Valeo Pharma to Host Second Quarter 2022 Results Conference Call / Webcast

June 8, 2022 (Source) — Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (“Valeo” or the “Company“), a Canadian pharmaceutical […]


Valeo Pharma Announces Results of Annual Meeting of Shareholders, Appointments and Options and RSU Grants

April 28, 2022 (Source) – Valeo Pharma Inc. (TSX:VPH) (OTCQB: VPHIF) (FSE:VP2) (“Valeo” or the “Company“), a Canadian pharmaceutical company, […]


Valeo Pharma to Present at the 2022 Bloom Burton & Co Healthcare Investor Conference

April 25, 2022 (Source) – Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (“Valeo” or the “Company“), a Canadian pharmaceutical […]


Valeo Pharma Announces Listing of Convertible Debentures on TSX

April 19, 2022 (Source) – Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (“Valeo” or the “Company“), a Canadian pharmaceutical […]


Valeo Pharma Announces Listing to the Toronto Stock Exchange

The Company’s shares and warrants to start trading on March 29th, 2022 March 28, 2022 (Source) — Valeo Pharma Inc. (TSX: VPH) (OTCQB: […]